Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 pharmacodynamics in healthy adults using insomnia model
NCT03284931Phase 1Completed
- Sponsor
- Biogen
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zuranolone in Insomnia, major depressive disorder (MDD) and postpartum depression (PPD) (3 arms), sponsored by Biogen. Primary endpoint: Sleep efficiency at 16 days. Started Sep 2017; status: completed.
02
Drugs
zuranolone
03
Conditions
Insomniamajor depressive disorder (MDD)postpartum depression (PPD)
Beyond the preview
Go deeper on NCT03284931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284931.